Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina

NCT04673279 | Completed

• 1 other identifier: 3545
• Study Type: observational
• Target: 189
• Locations: 1 country
• Sites: 1

Brief Summary

Between June 10t h and July 1st, a cross-sectional design study in an Argentina slum, showed a prevalence based on immunoglobuling G-class (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) of 53.4%. It remains unanswered whether natural infection produces sustained antibodies. The aim of this study is to evaluate the presence of IgG antibodies for Coronavirus disease 2019 (COVID-19) after 5 months in inhabitants of Barrio 31 who consented the Seroprevalence Study for COVID-19.

Conditions

Coronavirus Disease 2019

Keywords

Immunity; serology; antibody; SARS-CoV-2; COVID-19; vulnerability

Outcome Measures

Primary Outcomes (1)

• to estimate the proportion of people with positive IgG antibodies for COVID-19 who have positive IgG antibodies after 5 month of the first measurement

  to estimate the proportion of people with positive IgG antibodies for COVID-19 who have positive IgG antibodies after 5 month of the first measurement

  up to 20 weeks

Secondary Outcomes (1)

• to estimate the proportion of people with positive IgG antibodies for dengue

  up to 20 weeks

Interventions

serology DIAGNOSTIC_TEST

An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.

Eligibility Criteria

• Age: 14 Years - 90 Years
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

inhabitants of Barrio Mugica: men and women form 14 years of age or older who were included in the first seroprevalence study carried on between Between June 10t h and July 1st, and who have positive antibodies against severe acute respiratory syndrome coronavirus 2

You may qualify if:

• Men and women form 14 years of age or older who were included in the seroprevalence study and who have positive antibodies against severe acute respiratory syndrome coronavirus 2

You may not qualify if:

• deny consent

Sponsors & Collaborators

• Hospital Italiano de Buenos Aires: lead
• Hospital de Niños R. Gutierrez de Buenos Aires: collaborator
• Ministerio de Salud GCBA: collaborator

Study Sites (1)

Hospital de Niños Ricardo Gutierrez

Buenos Aires, Buenos Aires F.D., C1425EFD, Argentina

Location

Related Publications (5)

• Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020 Mar 26;368:m1198. doi: 10.1136/bmj.m1198. No abstract available.

  PMID: 32217618 BACKGROUND

• Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.

  PMID: 32555424 BACKGROUND

• Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol. 2020 Aug;101(8):791-797. doi: 10.1099/jgv.0.001439.

  PMID: 32430094 BACKGROUND

• Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, Gubler DJ. Preventing Dengue Epidemics during the COVID-19 Pandemic. Am J Trop Med Hyg. 2020 Aug;103(2):570-571. doi: 10.4269/ajtmh.20-0480. Epub 2020 Jun 15. No abstract available.

  PMID: 32539912 BACKGROUND

• Cardoso MR, Cousens SN, de Goes Siqueira LF, Alves FM, D'Angelo LA. Crowding: risk factor or protective factor for lower respiratory disease in young children? BMC Public Health. 2004 Jun 3;4:19. doi: 10.1186/1471-2458-4-19.

  PMID: 15176983 BACKGROUND

Related Links

• 2019 Novel Coronavirus (COVID-19) Pneumonia with Hemoptysis as the Initial Symptom: CT and Clinical Features
• SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19
• Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research.
• Reductions in commuting mobility correlate with geographic differences in SARS-CoV-2 prevalence in New York City
• The COVID-19 pandemic should not jeopardize dengue control

Biospecimen

Retention: SAMPLES WITHOUT DNA

blod samples for antibodies detection against dengue

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Vanina Pagotto, MD MG

  Hospital Italiano de Buenos Aires

  STUDY CHAIR

• Alicia Mistchenko, Phd

  Hospital de Niños Ricardo Gutierrez

  PRINCIPAL INVESTIGATOR

• Silvana Figar, MD MG

  Hospital Italiano de Buenos Aires

  STUDY CHAIR

• Andrea Gamarnick, Phd

  National Council of Scientific and Technical Research, Argentina

  STUDY CHAIR

• Ana Maria Gomez Saldaño, MD MG

  Salud Comunitaria Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires

  STUDY CHAIR

• Lorena Luna

  Salud Comunitaria Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires

  STUDY CHAIR

• Julieta Salto

  Salud Comunitaria Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires

  STUDY CHAIR

• Magdalena Wagner Manslau

  Salud Comunitaria Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires

  STUDY CHAIR

• Fernan Quiroz, MD MG

  Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: principal investigator

Study Record Dates

• First Submitted: December 13, 2020
• First Posted: December 17, 2020
• Study Start: December 2, 2020
• Primary Completion: August 20, 2021
• Study Completion: August 20, 2021
• Last Updated: August 25, 2021

Record last verified: 2021-08

Locations

AR (1)